Lupin has signed a license and supply agreement with OLIC (Thailand) LTD. (OLIC), a subsidiary of the renowned Japanese pharmaceutical company Fuji Pharma Co., Ltd. (Fuji), for marketing Nextstellis (drospirenone and estetrol tablets) in Vietnam and Philippines.

Nextstellis is a novel combination medication comprising of drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy.

“We are delighted to collaborate with Fuji and OLIC to offer NextstellisTM to our patients in Vietnam and the Philippines. This new addition to our Women’s Health portfolio will strengthen our commitment to expand healthcare options worldwide,” said Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.

Fuji is a Tokyo Stock Exchange (TSE) listed, Japan?based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products.

Fuji focuses on the field of women’s health care with a wide variety of new and generic drugs for women’s specific diseases such as infertility, dysmenorrhea, endometriosis, contraception, and menopausal disorders. Fuji aims to be a leading company in women’s healthcare and support health of women of all ages.